Apexigen, Inc., — a clinical-stage biopharmaceutical company focusing on discovering and developing antibody-based therapeutics for the treatment of cancer with an emphasis on new Immuno-Oncology (I-O) agents, today announced the receipt of a milestone payment under a license agreement for its proprietary APXiMAB™ technology. The milestone payment was associated with the achievement of a clinical development milestone. “Our proprietary technology platform enables the discovery of high-quality antibodies, even against very challenging targets. We are excited to see our collaborators drive the clinical development of six of our antibodies, supporting our common goal of delivering novel therapies to patients,” said Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer of Apexigen.